Nieves Martinez Lago, Specialist in the Field (FEA) of Medical Oncology at University Hospital Complex of Santiago de Compostela, shared a post on X:
“Tarlatamab (DLL3) in MTC
- Case series (n=4): heavily pretreated MTC
- ORR 67% (2 PR, 1 SD evaluable)
- 100% clinical/biochemical activity signal
Safety concerns: G≥3 TRAEs in all pts (CRS, ICANS, G5 perforation)
Promising activity, but dosing/safety need optimization ”
Title: Preliminary Safety and Efficacy of Tarlatamab in Medullary Thyroid Carcinoma
Authors: Thomas Roberts, Kartik Sehgal, Steven DuBois, Jason Hornick, Antonio Perez-Atayde, Stephan Voss, Justine Barletta, Alexandra Sala, Amber Miller, Martha Lodyga, Catherine Meador, Lori Wirth
Other articles featuring Nieves Martinez Lago on OncoDaily.
